ZYME

In August 2026, Zymeworks' partner Jazz Pharmaceuticals secured FDA approval for Ziihera (zanidatamab) in two combination regimens for the first-line treatment of HER2-positive gastroesophageal adenocarcinoma, which served as a significant positive catalyst and led to analyst price target increases. In June 2026, Zymeworks announced and completed the acquisition of Theravance Biopharma, an action expected to diversify cash flows, add revenue-generating assets like YUPELRI®, and provide commercial, royalty, and R&D value. In September 2026, Zymeworks issued updated 2026 financial guidance, projecting total revenue between $278 million and $292 million and adjusted EBITDA between $114 million and $128 million. On October 9, 2026, Adam Schayowitz, EVP and Head of Research & Development, executed a non-discretionary 'sell to cover' transaction, selling 13,832 shares of ZYME common stock to cover tax withholding obligations related to restricted stock unit vesting. Throughout this period, analysts maintained a 'Buy' consensus rating for ZYME, with several firms raising their price targets following positive developments.